Navigation Links
Bortezomib shows promise in reducing GVHD and reconstituting immune system in some patients
Date:12/6/2009

NEW ORLEANSA drug that has become a mainstay of multiple myeloma treatment may outperform alternative therapies in re-establishing the immune system of patients who have received stem cell transplants from unrelated, partially matched donors, according to early clinical trial results to be presented by

Dana-Farber Cancer Institute investigators at the American Society of Hematology's (ASH) annual meeting on Sunday, Dec. 6 (Abstract 48, Ernest N. Morial Convention Center, Room 243-245, 5:45 pm CT).

The trial was designed to determine whether the drug bortezomib (trade name Velcade), when added to routine agents (tacrolimus, methotrexate), can improve control of graft-versus-host disease (GVHD) and improve immune system recovery following a transplant from a mismatched-unrelated donor. GVHD is a common and potentially severe side effect of blood-forming stem cell transplants, in which donor immune cells attack normal patient cells and tissues. GVHD is more frequent in patients receiving transplants from mismatched-unrelated donors (in comparison with matched-related donors).

Based on bortezomib's effect in preclinical models, and in multiple myeloma patients who have received donor stem cell transplants, Dana-Farber's John Koreth, MBBS, DPhil, and colleagues theorized that it could help control the overactivity of immune cells responsible for GVHD in stem cell transplant patients.

Bortezomib inhibits the activity of antigen-presenting cells, which help initiate the immune attack in GVHD, and reduces activity of an important protein called nuclear factor-B in T cells, which undertake the immune attack. In preclinical studies, bortezomib has been shown to selectively deplete T cells that can target patients' normal cells. Mouse transplant studies have shown that early administration of bortezomib protects against GVHD without reducing the transplanted stem cells' ability to settle in the bone ma
'/>"/>

Contact: Teresa Herbert
teresa_herbert@dfci.harvard.edu
617-632-5653
Dana-Farber Cancer Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Data on VELCADE(R) (Bortezomib) for Injection Based Therapies to be Presented at the International Myeloma Workshop
2. FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
3. Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients
4. Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
5. VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial
6. Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma
7. Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy
8. ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity
9. FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma
10. New drug shows promise for those with clotting disorders: McMaster researcher
11. Congress Has Allowed Most Previous Medicare Cuts to Take Effect, New Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... U.S. Pharmacopeial Convention is pleased to announce that Gigi ... North Carolina State’s College of Veterinary Medicine has been ... Distinguished Volunteer Service—the organization’s highest award. , Since ... experts to direct its work to improve the health ...
(Date:1/22/2015)... Hollywood, California (PRWEB) January 22, 2015 The City ... 2015 at 10 a.m., to commemorate the 42nd anniversary of the ... United States. , “It’s been 42 years since the Roe vs. ... choose is still as present as ever,” said City of West ...
(Date:1/22/2015)... AZ (PRWEB) January 22, 2015 Padre Murphy's ... long supporter of Pro Player Health Alliance (PPHA). ... Padre Murphy's in getting everyone, including NFL greats, treated for ... of the leading groups supporting the cause in the valley. ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 Angelweddingdress is a ... business invites its customers to follow it on Facebook, Twitter, ... a Valentine’s Day gift. Angelweddingdress draws a lottery every week. ... Sale to Feb. 28, 2015. Click Angelweddingdress homepage ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 The ... ) in the U.S. District Court, Southern District of West ... Bard, Inc. in that proceeding’s first bellwether trial. In an ... for a new trial after finding that C.R. Bard had ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4
... of doctors and their patients with diabetes do not see ... manage, according to a survey by the University of Michigan ... and hypertension among their top concerns, 38 percent of doctors ... while only 18 percent of diabetics said it was the ...
... ... a distribution agreement to provide GuardRFID’s Active RFID platform to its Healthcare, Government and ... ... with VT Milcom of Virginia Beach, Va. to provide its next generation RFID platform ...
... , ... Feb. 2 Hospitals in the Boston area ... (ICUs) prevent central-line bloodstream infections, a cause of death, disability, and ... February 2 , www.ConsumerReportsHealth.org will post hospital infection rates ...
... , RANCHO CORDOVA, Calif. , ... the delivery of eyecare and eyewear through innovative business solutions ... Jr. as its chief financial officer. Ball will replace ... recently retired after 31 years, and report to chief executive ...
... ... Hospitals in Los Angeles vary dramatically in terms ... a cause of death, disability, and expense in our nations, hospitals that ... post hospital infection rates for 41 Los Angeles area hospitals, ...
... ... patient safety information in the public eye , YONKERS, N.Y. ... Tampa / St. Petersburg area vary dramatically in terms of how ... of death, disability, and expense in our nations, hospitals that is largely ...
Cached Medicine News:Health News:Diabetes patients rank health concerns differently than their doctors, U-M survey shows 2Health News:Guard RFID Solutions Inc. and VT Milcom Enter into Distribution Agreement 2Health News:Consumer Reports Health: Central-Line Infection Rates In Boston Hospitals Vary Dramatically; Some Hospitals Not Reporting 2Health News:Consumer Reports Health: Central-Line Infection Rates In Boston Hospitals Vary Dramatically; Some Hospitals Not Reporting 3Health News:Consumer Reports Health: Central-Line Infection Rates In Boston Hospitals Vary Dramatically; Some Hospitals Not Reporting 4Health News:Consumer Reports Health: Central-Line Infection Rates In Boston Hospitals Vary Dramatically; Some Hospitals Not Reporting 5Health News:Consumer Reports Health: Central-Line Infection Rates In Boston Hospitals Vary Dramatically; Some Hospitals Not Reporting 6Health News:Consumer Reports Health: Central-Line Infection Rates In Boston Hospitals Vary Dramatically; Some Hospitals Not Reporting 7Health News:VSP Global Appoints New Chief Financial Officer 2Health News:Consumer Reports Health: Central-Line Infection Rates in Los Angeles Hospitals Vary Dramatically; Some Hospitals Not Reporting 2Health News:Consumer Reports Health: Central-Line Infection Rates in Los Angeles Hospitals Vary Dramatically; Some Hospitals Not Reporting 3Health News:Consumer Reports Health: Central-Line Infection Rates in Los Angeles Hospitals Vary Dramatically; Some Hospitals Not Reporting 4Health News:Consumer Reports Health: Central-Line Infection Rates in Los Angeles Hospitals Vary Dramatically; Some Hospitals Not Reporting 5Health News:Consumer Reports Health: Central-Line Infection Rates in Los Angeles Hospitals Vary Dramatically; Some Hospitals Not Reporting 6Health News:Consumer Reports Health: Central-Line Infection Rates in Los Angeles Hospitals Vary Dramatically; Some Hospitals Not Reporting 7Health News:Consumer Reports Health: Central-Line Infection Rates in Los Angeles Hospitals Vary Dramatically; Some Hospitals Not Reporting 8Health News:Consumer Reports Health: Central-Line Infection Rates in Tampa-St. Petersburg Area Hospitals Vary Dramatically 2Health News:Consumer Reports Health: Central-Line Infection Rates in Tampa-St. Petersburg Area Hospitals Vary Dramatically 3Health News:Consumer Reports Health: Central-Line Infection Rates in Tampa-St. Petersburg Area Hospitals Vary Dramatically 4Health News:Consumer Reports Health: Central-Line Infection Rates in Tampa-St. Petersburg Area Hospitals Vary Dramatically 5Health News:Consumer Reports Health: Central-Line Infection Rates in Tampa-St. Petersburg Area Hospitals Vary Dramatically 6
(Date:1/23/2015)... Jan. 23, 2015 Cord Blood America, Inc. ( www.cordblood-america.com ... the "Company")  filed a Preliminary Proxy Statement, Schedule 14A, with ... and provides an update for shareholders detailing why a "YES" ... Dear Shareholders, As we reflect upon ...
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft ... Company,s Phase 2 clinical trial.  This open-label study will ... GPX-150 (an investigational medication), in approximately 30 adults as ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 ...
(Date:1/22/2015)... 22, 2015  BiOptix is pleased to announce the appointment ... of Chemistry and Biochemistry. Scott joins the company after previous ... Amgen throughout the course of his nearly 20 year ... is a nationally recognized thought leader in the biosensor ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... Trellis Infusion Catheter enables the physician to ... fluid, and disperse the agent by means ... Trellis is a multi-lumen catheter with two ... and infusion holes located between these balloons. ...
... ACRYSOF® UV-absorbing acrylic foldable single-piece posterior chamber ... of the human crystalline lens in the ... years of age and older. The optical ... soft acrylic material. These lenses have biconvex ...
... All USIOL lenses are manufactured ... and processes. Perspex CQ UV ... the multi-piece and single piece ... available in both nonphaco and ...
Single piece PMMA lens, AC depth: 4.9, 2 suture holes....
Medicine Products: